• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

TNF Gene Record

  • Summary
  • Interactions
  • Claims
  • TNF 7124 Druggable Genome

    Alternate Names:

    7124
    TUMOR NECROSIS FACTOR
    TNF
    DIF
    TNF-alpha
    TNFA
    TNFSF2
    TNLG1F
    191160
    11892
    ENSG00000232810
    OTTHUMG00000031194
    P01375
    TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 2
    CACHECTIN
    TNF-A
    ENSG00000204490; ENSG00000206439; ENSG00000228321; ENSG00000228849; ENSG00000230108; ENSG00000223952; ENSG00000232810
    N-terminal fragment
    Tumor necrosis factor, soluble form
    C-domain 2
    C-domain 1
    Intracellular domain 2
    Intracellular domain 1
    Tumor necrosis factor, membrane form
    ICD2
    ICD1
    NTF
    PA435
    TNFA_HUMAN
    T20178

    Gene Info:

    Target Class Miscellaneous
    Target Subclass Ligand
    Target Subclass Cytokine
    Target Class Other
    Target Main Class Other
    Transmembrane Helix Count 1
    Gene Biotype PROTEIN_CODING
    (9 More Sources)

    Gene Categories: Category Details

    CELL SURFACE
    EXTERNAL SIDE OF PLASMA MEMBRANE
    DRUGGABLE GENOME

    Publications:

    van den Borne et al., 1997, Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral blood mononuclear cells., J. Rheumatol.
    Chapman et al., 2006, Seizure duration following sarin exposure affects neuro-inflammatory markers in the rat brain., Neurotoxicology
    Kim SH et al., 2012, TNF-α genetic polymorphism -308G/A and antituberculosis drug-induced hepatitis., Liver Int
    Vincent, 2000, Afelimomab., Int. J. Clin. Pract.
    Mimura, 2007, [Selection of one of the TNF blockers; infliximab and etanercept]., Nippon Rinsho
    Magro et al., 2005, Reactive hepatitis in a patient with Crohn's disease successfully treated with infliximab: does tumor necrosis factor alpha play a role in reactive hepatitis?, Inflamm. Bowel Dis.
    Sapienza et al., 2004, Treatment of pyoderma gangrenosum with infliximab in Crohn's disease., Dig. Dis. Sci.
    Shen et al., 2005, Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept., Aliment. Pharmacol. Ther.
    Braun et al., 2005, Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept., Arthritis Rheum.
    Mori et al., 2006, Pneumocystis jiroveci pneumonia in a patient with rheumatoid arthritis as a complication of treatment with infliximab, anti-tumor necrosis factor alpha neutralizing antibody., Mod Rheumatol
    Maini et al., 2002, How does infliximab work in rheumatoid arthritis?, Arthritis Res.
    Popa et al., 2005, Cytokine production of stimulated whole blood cultures in rheumatoid arthritis patients receiving short-term infliximab therapy., Cytokine
    Tobin et al., 2005, TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis., BioDrugs
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Danese et al., 2006, TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease., J. Immunol.
    Song GG et al., 2015, Association between TNF-α (-308 A/G, -238 A/G, -857 C/T) polymorphisms and responsiveness to TNF-α blockers in spondyloarthropathy, psoriasis and Crohn's disease: a meta-analysis., Pharmacogenomics
    Swierkot J et al., 2015, Analysis of associations between polymorphisms within genes coding for tumour necrosis factor (TNF)-alpha and TNF receptors and responsiveness to TNF-alpha blockers in patients with rheumatoid arthritis., Joint Bone Spine
    Tong Q et al., 2013, Association of TNF-α polymorphism with prediction of response to TNF blockers in spondyloarthritis and inflammatory bowel disease: a meta-analysis., Pharmacogenomics
    Tong Q et al., 2012, TNF-α -857 and -1031 polymorphisms predict good therapeutic response to TNF-α blockers in Chinese Han patients with ankylosing spondylitis., Pharmacogenomics
    Lacruz-Guzmán D et al., 2013, Influence of polymorphisms and TNF and IL1β serum concentration on the infliximab response in Crohn's disease and ulcerative colitis., Eur J Clin Pharmacol
    Zeng Z et al., 2013, Association between tumor necrosis factor-α (TNF-α) promoter -308 G/A and response to TNF-α blockers in rheumatoid arthritis: a meta-analysis., Mod Rheumatol
    Daïen CI et al., 2012, TGF beta1 polymorphisms are candidate predictors of the clinical response to rituximab in rheumatoid arthritis., Joint Bone Spine
    O'Rielly DD et al., 2009, TNF-alpha-308 G/A polymorphism and responsiveness to TNF-alpha blockade therapy in moderate to severe rheumatoid arthritis: a systematic review and meta-analysis., Pharmacogenomics J
    Maxwell JR et al., 2008, Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis., Hum Mol Genet
    Marotte H et al., 2008, Association between the level of circulating bioactive tumor necrosis factor alpha and the tumor necrosis factor alpha gene polymorphism at -308 in patients with rheumatoid arthritis treated with a tumor necrosis factor alpha inhibitor., Arthritis Rheum
    Guis S et al., 2007, Influence of -308 A/G polymorphism in the tumor necrosis factor alpha gene on etanercept treatment in rheumatoid arthritis., Arthritis Rheum
    Miceli-Richard C et al., 2008, A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis., Ann Rheum Dis
    Cuchacovich M et al., 2006, Tumour necrosis factor (TNF)alpha -308 G/G promoter polymorphism and TNFalpha levels correlate with a better response to adalimumab in patients with rheumatoid arthritis., Scand J Rheumatol
    Lee YH et al., 2006, Association of TNF-alpha -308 G/A polymorphism with responsiveness to TNF-alpha-blockers in rheumatoid arthritis: a meta-analysis., Rheumatol Int
    Seitz M et al., 2007, The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients., Rheumatology (Oxford)
    Kang et al., 2005, The influence of a polymorphism at position -857 of the tumour necrosis factor alpha gene on clinical response to etanercept therapy in rheumatoid arthritis., Rheumatology (Oxford)
    Mugnier B et al., 2003, Polymorphism at position -308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis., Arthritis Rheum
    Louis E et al., 2002, A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism., Scand J Gastroenterol
    Friedland et al., 1993, Comparison of endotoxin release by different antimicrobial agents and the effect on inflammation in experimental Escherichia coli meningitis., J. Infect. Dis.
    Bessler et al., 2000, Effect of cefotaxime on cytokine production in newborns and adults in vitro., Biomed. Pharmacother.
    Björn N et al., 2020, Genes and variants in hematopoiesis-related pathways are associated with gemcitabine/carboplatin-induced thrombocytopenia., Pharmacogenomics J
    Lü et al., 2004, [Effect of clozapine and risperidone on serum cytokine levels in patients with first-episode paranoid schizophrenia]., Di Yi Jun Yi Da Xue Xue Bao
    Erbağci et al., 2001, Serum IL-1beta, sIL-2R, IL-6, IL-8 and TNF-alpha in schizophrenic patients, relation with symptomatology and responsiveness to risperidone treatment., Mediators Inflamm.
    Bang et al., 2004, Adalimumab: a review of its use in rheumatoid arthritis., BioDrugs
    Aguillón et al., 2003, [New immunological weapons for medicine in the 21st Century: biological therapy based on the use of the latest generation monoclonal antibodies]., Rev Med Chil
    Klinkhoff, 2004, Biological agents for rheumatoid arthritis: targeting both physical function and structural damage., Drugs
    Flendrie et al., 2003, Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis., Ann. Rheum. Dis.
    Lorenz, 2002, Technology evaluation: adalimumab, Abbott laboratories., Curr. Opin. Mol. Ther.
    Rajkumar, 2001, Thalidomide in the treatment of multiple myeloma., Expert Rev Anticancer Ther
    Enomoto et al., 2002, Thalidomide prevents alcoholic liver injury in rats through suppression of Kupffer cell sensitization and TNF-alpha production., Gastroenterology
    Vescovo et al., 2002, Effect of thalidomide on the skeletal muscle in experimental heart failure., Eur. J. Heart Fail.
    Turk et al., 1996, Binding of thalidomide to alpha1-acid glycoprotein may be involved in its inhibition of tumor necrosis factor alpha production., Proc. Natl. Acad. Sci. U.S.A.
    Fu et al., 2002, Thalidomide and tuberculosis., Int. J. Tuberc. Lung Dis.
    Richardson et al., 2002, Thalidomide in multiple myeloma., Biomed. Pharmacother.
    Sugimoto et al., 2006, Influences of proinflammatory and anti-inflammatory cytokine polymorphisms on eradication rates of clarithromycin-sensitive strains of Helicobacter pylori by triple therapy., Clin. Pharmacol. Ther.
    Park et al., 1999, Structural basis for self-association and receptor recognition of human TRAF2., Nature
    Calabrese, 1999, Rheumatoid arthritis and primary care: the case for early diagnosis and treatment., J Am Osteopath Assoc
    Sandborn et al., 1999, Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety., Inflamm. Bowel Dis.
    Moreland, 1999, Inhibitors of tumor necrosis factor: new treatment options for rheumatoid arthritis., Cleve Clin J Med
    Grell et al., 1999, Induction of cell death by tumour necrosis factor (TNF) receptor 2, CD40 and CD30: a role for TNF-R1 activation by endogenous membrane-anchored TNF., EMBO J.
    Liu, 1993, Expression of tumor necrosis factor and c-fos genes in peritoneal macrophages of hypothyroid mice., Inflammation
    Pirmohamed M et al., 2001, TNFalpha promoter region gene polymorphisms in carbamazepine-hypersensitive patients., Neurology
    Himmerich et al., 2005, Plasma levels of leptin and endogenous immune modulators during treatment with carbamazepine or lithium., Psychopharmacology (Berl.)
    Peng et al., 2001, Effects of early enteral feeding on the prevention of enterogenic infection in severely burned patients., Burns
    Pérez-Castrillón JL et al., 2008, Effect of the TNFalpha-308 G/A polymorphism on the changes produced by atorvastatin in bone mineral density in patients with acute coronary syndrome., Ann Nutr Metab
    Mittal et al., Golimumab and certolizumab: the two new anti-tumor necrosis factor kids on the block., Indian J Dermatol Venereol Leprol
    Oettinger et al., 2003, Microencapsulation of tumor necrosis factor oligomers: a new approach to proinflammatory cytokine inhibition., J. Interferon Cytokine Res.
    Natsume et al., 2002, Enhanced antitumor activities of TZT-1027 against TNF-alpha or IL-6 secreting Lewis lung carcinoma in vivo., Cancer Chemother. Pharmacol.
    Lee JH et al., 2013, Genetic predisposition of hand-foot skin reaction after sorafenib therapy in patients with hepatocellular carcinoma., Cancer
    Zhang et al., 1999, Effects of bacillus Calmette-Guèrin and interferon alpha-2B on cytokine production in human bladder cancer cell lines., J. Urol.
    Shin et al., 2002, Effects of rutin and harmaline on rat reflux oesophagitis., Auton Autacoid Pharmacol
    Manna et al., 1999, Suppression of tumor necrosis factor-activated nuclear transcription factor-kappaB, activator protein-1, c-Jun N-terminal kinase, and apoptosis by beta-lapachone., Biochem. Pharmacol.
    Beloeil et al., 2005, Bupivacaine's action on the carrageenan-induced inflammatory response in mice: cytokine production by leukocytes after ex-vivo stimulation., Anesth. Analg.
    Ventre et al., 1997, Targeted disruption of the tumor necrosis factor-alpha gene: metabolic consequences in obese and nonobese mice., Diabetes
    Reinehr et al., 2005, High-sensitive C-reactive protein, tumor necrosis factor alpha, and cardiovascular risk factors before and after weight loss in obese children., Metab. Clin. Exp.
    Leiba et al., 2006, Halofuginone inhibits NF-kappaB and p38 MAPK in activated T cells., J. Leukoc. Biol.
    Elias et al., 2004, Serum TNF-alpha in psoriasis after treatment with propylthiouracil, an antithyroid thioureylene., BMC Dermatol.
    Grinyó J et al., 2008, Association of four DNA polymorphisms with acute rejection after kidney transplantation., Transpl Int
    Chew CS et al., 2011, Tumour necrosis factor haplotypes associated with sensory neuropathy in Asian and Caucasian human immunodeficiency virus patients., Tissue Antigens
    Chiang et al., 2005, Pyridoxine supplementation corrects vitamin B6 deficiency but does not improve inflammation in patients with rheumatoid arthritis., Arthritis Res. Ther.
    Zeisig et al., 1995, Influence of hexadecylphosphocholine on the release of tumor necrosis factor and nitroxide from peritoneal macrophages in vitro., J. Cancer Res. Clin. Oncol.
    Nokta et al., 1997, Kinetics of tumor necrosis factor alpha and soluble TNFRII in HIV-infected patients treated with a triple combination of stavudine, didanosine, and hydroxyurea., AIDS Res. Hum. Retroviruses
    Miura et al., 2006, Anti-inflammatory effect of spironolactone on human peripheral blood mononuclear cells., J. Pharmacol. Sci.
    Gogusev et al., Regulation of TNF-alpha and IL-1 gene expression during TPA-induced differentiation of "Malignant histiocytosis" DEL cell line t(5;6) (q35:p21)., Anticancer Res.
    Mori et al., 2004, Comparison of the effects of glimepiride and glibenclamide on adipose tissue tumour necrosis factor-alpha mRNA expression and cellularity., Diabetes Obes Metab
  • GOLIMUMAB   TNF

    Interaction Score: 4.55

    Interaction Types & Directionality:
    antibody (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target
    Mechanism of Interaction TNF-alpha inhibitor

    PMIDs:
    21079302


    Sources:
    TdgClinicalTrial ChemblInteractions TEND TTD

  • PLACULUMAB   TNF

    Interaction Score: 2.73

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name ART621, PN0621
    Novel drug target Established target
    Mechanism of Interaction TNF-alpha inhibitor

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial ChemblInteractions TTD

  • OZORALIZUMAB   TNF

    Interaction Score: 1.82

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction TNF-alpha inhibitor
    Direct Interaction yes
    Trial Name ozoralizumab

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial ChemblInteractions

  • MEROPENEM   TNF

    Interaction Score: 1.82

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8354907


    Sources:
    NCI

  • PEGSUNERCEPT   TNF

    Interaction Score: 1.82

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction TNF-alpha inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions TTD

  • AFELIMOMAB   TNF

    Interaction Score: 1.82

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction TNF-alpha inhibitor

    PMIDs:
    10829362


    Sources:
    ChemblInteractions

  • INFLIXIMAB   TNF

    Interaction Score: 1.55

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name infliximab ,Remicade
    Novel drug target Established target
    Direct Interaction yes

    PMIDs:
    17642244 15674127 15481318 15691299 16052578 16622728 12110154 15804598 15691217 11752352 16456024 26244882 25311255 24192118 23057546 22960943 22760475 22129793 19365401 18713756 18438841 18050183 17673491 17343250 16909270 16720636 15695296 12847678 12190096


    Sources:
    TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD

  • ADALIMUMAB   TNF

    Interaction Score: 1.39

    Interaction Types & Directionality:
    antibody (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction TNF-alpha inhibitor
    Direct Interaction yes
    Trial Name Humira

    PMIDs:
    26244882 24192118 23057546 22960943 22760475 22129793 19365401 18713756 18438841 18050183 17343250 16909270 16720636 12847678 12190096 15046527 15022409 15200343 14532145 11752352 12044041


    Sources:
    TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD

  • ETANERCEPT   TNF

    Interaction Score: 1.24

    Interaction Types & Directionality:
    antibody (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction TNF-alpha inhibitor
    Trial Name Enbrel

    PMIDs:
    10206649 10405518 10338381 10375846 11752352 10357816 26244882 24192118 23057546 22960943 22760475 22129793 19365401 18713756 18438841 18050183 17343250 16909270 16720636 12847678 12190096


    Sources:
    TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD

  • LENABASUM   TNF

    Interaction Score: 0.91

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • SOBLIDOTIN   TNF

    Interaction Score: 0.91

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11855751


    Sources:
    NCI

  • LENERCEPT   TNF

    Interaction Score: 0.91

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction TNF-alpha inhibitor

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • CERTOLIZUMAB   TNF

    Interaction Score: 0.91

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • NERELIMOMAB   TNF

    Interaction Score: 0.91

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction TNF-alpha inhibitor

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • ENBREL   TNF

    Interaction Score: 0.91

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • CERTOLIZUMAB PEGOL   TNF

    Interaction Score: 0.91

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction TNF-alpha inhibitor

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • AZ9773   TNF

    Interaction Score: 0.91

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction TNF-alpha inhibitor

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • ONERCEPT   TNF

    Interaction Score: 0.91

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction TNF-alpha inhibitor

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • PYRIDOXINE   TNF

    Interaction Score: 0.61

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16277693


    Sources:
    NCI

  • REMTOLUMAB   TNF

    Interaction Score: 0.45

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • PF-04236921   TNF

    Interaction Score: 0.45

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name PF-04236921
    Novel drug target Established target

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial

  • ETHAMBUTOL   TNF

    Interaction Score: 0.45

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22151084


    Sources:
    PharmGKB

  • LACTULOSE   TNF

    Interaction Score: 0.45

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11226652


    Sources:
    NCI

  • ABBV-257   TNF

    Interaction Score: 0.45

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • CEFOTAXIME   TNF

    Interaction Score: 0.45

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8354907 10989981


    Sources:
    NCI

  • MILTEFOSINE   TNF

    Interaction Score: 0.36

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    7883777


    Sources:
    NCI

  • BENZO[E]PYRENE   TNF

    Interaction Score: 0.3

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • NAFAMOSTAT   TNF

    Interaction Score: 0.3

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • HALOFUGINONE   TNF

    Interaction Score: 0.3

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16769768


    Sources:
    NCI

  • THALIDOMIDE   TNF

    Interaction Score: 0.26

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name Thalomid

    PMIDs:
    12113124 12105857 12167383 8755512 11752352 12102294 12046682


    Sources:
    TdgClinicalTrial TEND TTD

  • 5,7-DIHYDROXY-4-METHYLCOUMARIN   TNF

    Interaction Score: 0.23

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • GLIMEPIRIDE   TNF

    Interaction Score: 0.23

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    14686960


    Sources:
    NCI

  • ORTATAXEL   TNF

    Interaction Score: 0.23

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • CELASTROL   TNF

    Interaction Score: 0.23

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • PYRAZINAMIDE   TNF

    Interaction Score: 0.23

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22151084


    Sources:
    PharmGKB

  • DERSALAZINE   TNF

    Interaction Score: 0.23

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name dersalazine sodium
    Novel drug target Established target

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial

  • BUPIVACAINE   TNF

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15781526


    Sources:
    NCI

  • RUTIN   TNF

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12423426


    Sources:
    NCI

  • VADIMEZAN   TNF

    Interaction Score: 0.18

    Interaction Types & Directionality:
    inducer (activating)

    Interaction Info:
    Notes

    PMIDs:
    None found


    Sources:
    TALC

  • HYDROXYCHLOROQUINE   TNF

    Interaction Score: 0.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9002011


    Sources:
    NCI

  • DIDANOSINE   TNF

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9430255


    Sources:
    NCI

  • BCG VACCINE   TNF

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10022737


    Sources:
    NCI

  • RABEPRAZOLE   TNF

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16815316


    Sources:
    NCI

  • ISONIAZID   TNF

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22151084


    Sources:
    PharmGKB

  • AMPHOTERICIN B   TNF

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • STAVUDINE   TNF

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20887379


    Sources:
    PharmGKB

  • LENALIDOMIDE   TNF

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    ClearityFoundationClinicalTrial TTD

  • PROPYLTHIOURACIL   TNF

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15119959


    Sources:
    NCI

  • METHYLENE BLUE   TNF

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • METHIMAZOLE   TNF

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8491516


    Sources:
    NCI

  • ALTEPLASE   TNF

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8615653


    Sources:
    NCI

  • SPIRONOLACTONE   TNF

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16837769


    Sources:
    NCI

  • RIFAMPIN   TNF

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22151084


    Sources:
    PharmGKB

  • GENTAMICIN   TNF

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    14565862


    Sources:
    NCI

  • CARBAMAZEPINE   TNF

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11294926 15565432


    Sources:
    NCI PharmGKB

  • LAPACHONE   TNF

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10075082


    Sources:
    NCI

  • OMEPRAZOLE   TNF

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16815316


    Sources:
    NCI

  • INSULIN   TNF

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9287059 16125526


    Sources:
    NCI

  • RISPERIDONE   TNF

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15567770 11545247


    Sources:
    NCI

  • MIDAZOLAM   TNF

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16406030


    Sources:
    NCI

  • HOMIDIUM BROMIDE   TNF

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • ATORVASTATIN   TNF

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18997459


    Sources:
    PharmGKB

  • CYCLOSPORINE   TNF

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18444945


    Sources:
    PharmGKB

  • PENTOXIFYLLINE   TNF

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • DIGOXIN   TNF

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CARBOPLATIN   TNF

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    31616045


    Sources:
    PharmGKB

  • SORAFENIB   TNF

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22736425


    Sources:
    PharmGKB

  • GEMCITABINE   TNF

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    31616045


    Sources:
    PharmGKB

  • Ensembl: ENSG00000232810

    • Version: 101_38

    Alternate Names:
    TNF Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • TEND: P01375

    • Version: 01-August-2011

    Alternate Names:
    P01375 Uniprot Accession
    ENSG00000204490; ENSG00000206439; ENSG00000228321; ENSG00000228849; ENSG00000230108; ENSG00000223952; ENSG00000232810 Ensembl Gene Id
    TNF Gene Symbol

    Gene Info:
    Target Main Class Other
    Target Subclass Ligand
    Transmembrane Helix Count 1

    Publications:

  • TdgClinicalTrial: P01375

    • Version: January-2014

    Alternate Names:
    TNF Gene Symbol

    Gene Info:
    Target Class Miscellaneous
    Target Subclass Ligand
    Target Subclass Cytokine

    Publications:

  • PharmGKB: TNF

    • Version: 18-August-2020

    Alternate Names:
    PA435 PharmGKB ID

    Gene Info:

    Publications:
    Björn N et al., 2020, Genes and variants in hematopoiesis-related pathways are associated with gemcitabine/carboplatin-induced thrombocytopenia., Pharmacogenomics J
    Seitz M et al., 2007, The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients., Rheumatology (Oxford)
    Lee YH et al., 2006, Association of TNF-alpha -308 G/A polymorphism with responsiveness to TNF-alpha-blockers in rheumatoid arthritis: a meta-analysis., Rheumatol Int

  • TTD: Tumor necrosis factor

    • Version: 2020.06.01

    Alternate Names:
    TNF TTD Gene Abbreviation
    T20178 TTD Target ID

    Gene Info:

    Publications:
    Libutti SK et al., 2010, Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal gold-rhTNF nanomedicine., Clin Cancer Res
    Assier E et al., 2012, Modulation of anti-tumor necrosis factor alpha (TNF-α) antibody secretion in mice immunized with TNF-α kinoid., Clin Vaccine Immunol

  • NCI: TNF

    • Version: 14-September-2017

    Alternate Names:

    Gene Info:

    Publications:
    van den Borne et al., 1997, Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral blood mononuclear cells., J. Rheumatol.
    Chapman et al., 2006, Seizure duration following sarin exposure affects neuro-inflammatory markers in the rat brain., Neurotoxicology
    Friedland et al., 1993, Comparison of endotoxin release by different antimicrobial agents and the effect on inflammation in experimental Escherichia coli meningitis., J. Infect. Dis.

  • HingoraniCasas: ENSG00000232810

    • Version: 31-May-2017

    Alternate Names:
    ENSG00000232810 Gene Symbol
    TNF Ensembl Id

    Gene Info:

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • TALC: TNF

    • Version: 12-May-2016

    Alternate Names:
    TNF Gene Symbol

    Gene Info:

    Publications:

  • ChemblInteractions: TNFA

    • Version: chembl_23

    Alternate Names:
    TNFSF2 GENE_SYMBOL
    TNF GENE_SYMBOL
    Tumor necrosis factor UNIPROT

    Gene Info:

    Publications:

  • GO: TNF

    • Version: 01-February-2022

    Alternate Names:
    TNFA GO Gene Synonym
    TNFSF2 GO Gene Synonym

    Gene Info:

    Gene Categories:
    CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE

    Publications:

  • Tempus: TNF

    • Version: 11-November-2018

    Alternate Names:
    TNF Gene Symbol

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • ClearityFoundationClinicalTrial: TNF

    • Version: 15-June-2013

    Alternate Names:

    Gene Info:

    Publications:

  • DTC: TNF

    • Version: 02-September-2020

    Alternate Names:

    Gene Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21